Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 10, Issue 3, Pages 503-512Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560802694713
Keywords
alogliptin; dipeptidyl peptidase-4; glucagon-like peptide-1; incretin; type 2 diabetes
Categories
Funding
- GlaxoSmithKline
- Novartis
- NovoNordisk
- Merck
- Lilly and Sanofi-aventis
Ask authors/readers for more resources
Background: Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clinical testing to support a new drug application for the treatment of type 2 diabetes. Objective: To provide an overview of the mechanism by which alogliptin reduces hyperglycemia and to summarize the pharmacology, efficacy and safety of the drug. Methods: A Medline search was conducted and abstracts and presentations from recent American Diabetes Association and European Association for the Study of Diabetes (EASD) meetings were reviewed. The results of Phase II and Phase III human studies were evaluated for clinical efficacy, safety and tolerability in patients with type 2 diabetes. Results/conclusions: Alogliptin is effective as a treatment for type 2 diabetes, either as monotherapy or in combination with metformin, thiazolidinediones, sulfonylureas and insulin. it is well tolerated and has an excellent safety profile. Additional studies are needed to evaluate the long-term safety and efficacy of alogliptin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available